

RESEARCH

Open Access



# The 30-day hospital readmission and mortality after surgery in colorectal cancer patients

Mesnad S. Alyabsi<sup>1,2,4,7\*</sup>, Anwar H. Alqarni<sup>2,6</sup>, Latifah M. Almutairi<sup>2,5</sup>, Mohammed A. Algarni<sup>2,3,4,5</sup>, Kanan M. Alshammari<sup>2,3,4,5</sup>, Adel Almutairi<sup>2,4,5</sup> and Nahar A. Alselaim<sup>2,4,5</sup>

## Abstract

**Purpose:** Hospital readmissions in the first weeks following surgery are common, expensive, and associated with increased mortality among colorectal cancer patients. This study is designed to assess the 30-day hospital readmission after colorectal cancer surgery and evaluate the risk factors that affect hospital readmission.

**Methods:** The study uses data from the Ministry of National Guard-Health Affairs Cancer Registry. All colorectal cancer patients who underwent colorectal cancer surgery between January 1, 2016, and November 31, 2021, were investigated. Factors examined were age, gender, marital status, Body Mass Index, Charlson Comorbidity Index, chemotherapy, radiotherapy, tumor stage, grade, site, surgical approach, length of stay, and discharge location. Kaplan–Meier curves were constructed to assess survival rates between readmitted and non-readmitted patients, and logistic regressions were performed to assess predictors of readmission.

**Results:** A total of 356 patients underwent tumor resection and 49 patients were readmitted within 30-day of index discharge. The most common reasons for hospital readmissions were gastrointestinal (22.45%), urinary tract infection (16.33%), and surgical site infection (12.24%). In the multivariable analysis, females were 89% more likely to be readmitted compared to males (odds ratio 1.89, 95% confidence intervals 1.00–3.58). Patients with distant metastatic tumors have higher odds of readmission (odds ratio 4.52, 95% confidence intervals 1.39–14.71) compared to patients with localized disease.

**Conclusions:** Colorectal cancer readmission is more common in patients with metastatic disease. Strategies to reduce readmission include planned transition to outpatient care, especially among patients with a high risk of readmission.

**Keywords:** Colorectal cancer, Patient readmission, Cancer registry, Surgery

## Introduction

Colorectal cancer (CRC) is the most diagnosed cancer in Saudi males and the third most common cancer in females, with a 5-year observed survival rate of 52%

[1,2]. Given the improved outcomes associated with the surgical resection of CRC, surgery remains the principal treatment modality for patients diagnosed with CRC [3]. Nonetheless, surgical outcomes including hospital readmission during the first weeks after surgery are prevalent, costly, and implicated with increased mortality [4–6]. Patients with cancer who have been discharged from hospitals have a readmission rate of up to 27% [7] and constitute a healthcare burden associated with morbidity and

\*Correspondence: mesnad@gmail.com

<sup>7</sup> King Abdullah International Medical Research Center, Mail Code 1515, P.O. Box 3660, Riyadh 11481, Saudi Arabia

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

mortality [4]. No prior studies assessed the CRC rate of hospital readmissions and the risk factors associated with readmission among the Saudi population.

International studies, however, have evaluated CRC surgical outcomes including the 30-day hospital readmission and its predictors. Several reasons were associated with readmission including age, gender, race/ethnicity, type of health insurance, socioeconomic status (SES), tumor stage, comorbidities, procedure type, surgical approach (open or laparoscopic), length of hospital stay (LOS), surgical complications, non-home discharge, blood transfusion, and stoma creation [8]. Whether the rate and predictors of CRC readmissions are the same in the Saudi population remains unknown. This is vital given the poor characteristics of CRC in the Saudi population such as late-stage at diagnosis and low survival [9].

In Saudi Arabia, the total number of surgeries during the year 2020 was 398,188 and 46,831 of them were implemented at the Ministry of National Guard- Health Affairs (MNG-HA) [10]. More than 80% of the CRC patients at the MNG-HA are treated surgically [11], and hence elucidating the surgical outcomes of these patients is crucial. Similar to the US Veteran Affairs (VA) health system, the MNG-HA is a health system that covers eligible members in all regions of Saudi Arabia. Moreover, at the national level, Saudi Arabia has developed 12 strategic programs including a health sector transformation program that is mainly focusing on improving the population's health through efficient use of resources.

The present study aims to assess the 30-day hospital readmission after index colorectal cancer surgery and evaluates the risk factors that impact hospital readmission. We principally focused on the impact of demographic variables, tumor characteristics including the stage at diagnosis and LOS. We also investigated the reasons for hospital readmission. Identifying the rate of readmission and its predictors will contribute to the development of interventions that should reduce readmission, hospitalization costs and improve cancer patient outcomes.

## Materials and methods

### Data sources

The current study is a retrospective cohort study that uses data from the MNG-HA Cancer Registry linked with BESTCare, a medical record database within the MNG-HA system. The cancer registry contains information on patients' demographics, clinical variables including tumor primary site, the stage at the time of diagnosis, and tumor grade for all patients who were diagnosed and treated at MNG-HA in Riyadh, Saudi Arabia. This study was approved by King Abdullah International Medical Research Center (NRC21R/432/10).

### Study population

All patients with histopathologically confirmed CRC diagnosis between January 1, 2016, and November 30, 2021, and  $\geq 18$  years old at the time of diagnosis among the MNG-HA population were included in the study. The MNG-HA population consists of military service members and their dependents, the civilian workforce, and healthcare students from the MNG-HA healthcare system. The population of more than one million individuals is served by tertiary care hospitals and four main primary and secondary care clinics.

### Study variables

#### Patient and tumor characteristics

Patient demographics were retrieved from the BESTCare system, including age at diagnosis, gender, marital status, and body mass index (BMI). Additional clinical variables such as comorbidities, chemotherapy, and radiotherapy were all retrieved. Inpatient records were used to gather surgical information such as type of surgery, LOS, surgery approach, operation duration, discharge location, admission, and discharge information.

Detailed tumor characteristics that were retrieved from the cancer registry include tumor site, topography, morphology, grade, and stage. The anatomic tumor location was categorized according to the International Classification of Diseases (ICD) for Oncology-third edition topography as follows: right colon (i.e., cecum, ascending colon, hepatic flexure of the colon, and transverse colon), left colon (i.e., splenic flexure of the colon, descending colon, and sigmoid), rectum (rectosigmoid junction and rectum) and colon not otherwise specified (NOS).

#### Outcome variables

CRC surgery was defined as the resection of the primary tumor with or without stoma creation within 1 month before or 12 months after CRC diagnosis. The 30-day readmission was defined as a hospitalization that occurred within 30 days of index discharge. Readmissions were identified using the inpatient records through admission and discharge dates. We also assessed overall survival in the study population. Follow-up time started from the index discharge date until the date of death, date of the last contact, or when the follow-up ended on January 31, 2022.

#### Statistical analysis

Categorical variables were assessed using the chi-square test and Fisher exact test. The student t-test was used for comparing means, while Wilcoxon tests for comparing medians. Penalized logistic regression models with Firth correction were used to estimate the univariate


and multivariable associations between readmission and covariates [1,2]. Forward elimination was used during the multivariable analysis with a criterion for entering variable to the model at  $P \leq 0.15$ . These variables were gender, marital status, stage at diagnosis, and discharge location. We compared the death rate between readmitted and non-readmitted patients and generated the survival curves using the Kaplan–Meier method. The differences in survival estimates were compared using the log-rank test. All statistical tests were 2-sided, and findings were considered statistically significant at  $P \leq 0.05$ . Data were analyzed using SAS statistical software version 9.4 (SAS Institute Inc. Cary, NC).

**Results**

Figure 1 shows the eligibility criteria for the study population. In the present study, 356 patients were included, and 49 (13.76%) of them were readmitted, while the remaining were non-readmitted patients (Table 1). The average age was 60.79 years with almost 60% of the sample being males and more than 78% were married. The average BMI was 27.28 kg/m<sup>2</sup> and nearly 70% of the patients did not have any comorbid conditions. Compared to the readmitted patients, non-readmitted individuals were more likely to be male and presented with regional stage at diagnosis. There was a significant association between stage at diagnosis and hospital readmission ( $P$  value = 0.03).

Table 2 displays the characteristics of the index surgery stratified by readmission status. The majority of the patients have a tumor located in the colon (83.71%) and the rest were in the rectum. Whereas 69.70% of the patients underwent open surgery, only 30.40% underwent laparoscopic surgery. Most patients had elective surgery (84.55%) and were discharged to the post-anesthesia care unit (82.87%). Furthermore, reasons for hospitalization after index discharge are reported in Table 3 and Additional file 1: Appendix 1. The recorded reasons were gastrointestinal (18.42% colon vs. 36.36% rectum), urinary tract infection (21.05% colon vs. 0% rectum), surgical site infection (13.16% colon vs. 9.09% rectum) and stoma related (2.63% colon vs. 27.27% rectum). Almost a quarter of readmission were due to gastrointestinal causes such as anastomotic leak, bowel obstruction, perforated tumor and rectal bleeding/discharge. Nevertheless, none of the differences were significant.

In the univariate analysis, there was a positive association between age and readmission and females had higher odds of readmission than males, but both did not reach a significance level (Table 4). On the contrary, compared to patients diagnosed with a localized tumor, those diagnosed with distant metastatic disease have 4.09 higher odds of readmission (odds ratio 4.09, 95%



**Fig. 1** Eligibility criteria for the study population

confidence intervals 1.29–12.98). Likewise, patients discharged to locations other than post-anesthesia care or ICU have 3.75 higher odds of readmission (odds ratio 3.75, 95% confidence intervals 1.19–11.80).

In the multivariable analysis, both patients diagnosed with distant metastatic tumors and those discharged to locations other than post-anesthesia care or ICU have higher odds of readmission (Table 4). Finally,

**Table 1** Patient characteristics by 30-days readmission status, NGHA 2016–2021 (N = 356)

	Readmitted		Non-readmitted		Total N, % or SD	P
	N	% or SD	N	% or SD		
Overall	49	13.76	307	86.23	356	
Age (mean, SD)	62.75	13.40	60.48	13.83	60.79 (13.77)	0.28
Gender						
Male	24	48.98	189	61.56	213 (59.83)	0.09
Female	25	51.02	118	38.44	143 (40.17)	
Marital status						0.43
Single	1	2.04	16	5.21	17 (4.78)	
Married	43	87.76	236	76.87	279 (78.37)	
Divorces/widowed	1	2.04	20	6.51	21 (5.90)	
Unknown	4	8.16	35	11.40	39 (10.96)	
Body mass index (kg/m <sup>2</sup> )	26.75	6.36	27.36	5.71	27.28 (5.80)	0.53
Charlson comorbidity index						0.68
0	36	73.47	210	68.40	246 (69.10)	
1	8	16.33	67	21.82	75 (21.07)	
> 1	5	10.20	30	9.77	35 (9.83)	
Stage at diagnosis						0.03
Distant metastasis	17	34.69	53	17.26	70 (19.66)	
Regional	27	55.10	195	63.52	222 (62.36)	
Localized	4	8.16	51	16.61	55 (15.45)	
Missing	1	2.04	8	2.61	9 (2.53)	
Pathological grading						0.44
Well differentiated	1	2.04	6	1.95	7 (1.97)	
Moderately differentiated	41	83.67	274	89.25	315 (88.48)	
Poorly differentiated	5	10.20	16	5.21	21 (5.90)	
Unknown	2	4.08	11	3.58	13 (3.65)	
Tumor morphology						0.46
Adenocarcinoma (AC), NOS	43	87.76	279	90.88	322 (90.45)	
Mucinous AC	2	4.08	6	1.95	8 (2.25)	
Others	4	8.16	22	7.17	26 (7.30)	
Tumor site						0.56
Right colon	6	12.24	53	17.26	59 (10.57)	
Left colon	20	40.82	125	40.72	145 (40.73)	
Colon-nonspecified	12	24.49	82	26.71	94 (26.40)	
Rectum	11	22.45	47	15.31	58 (16.29)	
Chemotherapy						0.38
Yes	7	14.29	31	10.10	38 (10.67)	
No	42	85.71	276	89.90	318 (89.33)	
Radiotherapy						0.18
Yes	19	38.78	90	29.32	109 (30.62)	
No	30	61.22	217	70.68	247 (69.38)	

for the mortality outcome, there is no statistically significant difference in the survivability amongst those readmitted and those not readmitted ( $P=0.0581$ ) (Fig. 2).

## Discussion

In this retrospective population-based cohort study, we found that 13.76% of CRC patients were readmitted within 30-day of index hospitalization, a finding that is

**Table 2** Index surgery characteristics by 30-days readmission status, NGHA 2016–2021 (N = 356)

	Readmitted		Non-readmitted		Total N, % or SD	P
	N	% or SD	N	% or SD		
Tumor location						
Colon	38	77.55	260	54.69	298 (83.71)	0.20
Rectum	11	22.45	47	15.31	58 (16.29)	
Surgery approach						
Laparoscopic	13	26.53	95	30.94	108 (30.43)	0.53
Open	36	73.47	212	69.06	248 (69.66)	
Surgery type						
Elective	43	87.76	258	84.04	301 (84.55)	0.84
Emergency	5	10.20	34	11.07	39 (10.96)	
Other	1	2.04	15	4.89	16 (4.49)	
LOS (median, IQR)	10.0	9.0	9.0	8.0	9.0 (8.0)	0.61
Discharge location						
Central Post Anesthesia Care Unit	38	77.55	257	83.71	295 (82.87)	0.05
Intensive Care Unit	6	12.24	41	13.36	47 (13.20)	
Other	5	10.20	9	2.93	14 (3.93)	
Operation time (minutes)	205.90	131.65	234.11	101.75	230.22 (106.60)	0.15

**Table 3** Reasons for 30-day hospital readmission after surgery (n = 49)

Reasons for readmission	Rectum N (%) N = 11	Colon N (%) N = 38	Total N (%) N = 49	P
Gastrointestinal	4 (36.36)	7 (18.42)	11 (22.45)	0.20
Urinary tract infection	0 (0)	8 (21.05)	8 (16.33)	0.21
Surgical site infection	1 (9.09)	5 (13.16)	6 (12.24)	0.71
Stoma related	3 (27.27)	1 (2.63)	4 (8.16)	0.08
Cardiovascular	0 (0)	2 (5.26)	2 (4.08)	1.0
Others	3 (27.27)	15 (39.47)	18 (36.73)	0.45

slightly higher than previous studies (9–11%) [4,12–17]. The majority of recorded reasons for hospital readmissions were gastrointestinal (22.45%), urinary tract infection (16.33%), and surgical site infection (12.24%). Almost one-quarter of metastatic patients were readmitted within 30 day of index hospitalization.

While previous studies found that 22% to 27% of metastatic CRC patients were readmitted [18–21,24], we observed that 24.30% (17/70) of our metastatic patients were readmitted. In the multivariable analysis, metastatic patients had 3.86 higher odds of 30-day hospital readmission compared to those with localized disease, similar to previous findings [22,23]. Several studies from Saudi Arabia have shown that a sizable percentage of Saudi CRC patients were diagnosed at an advanced stage [2,9], a risk factor that has been shown to increase readmission in our population. Moreover, we found that patients discharged to locations other than post anesthesia care unit were more likely to be readmitted.

Taken together, hospitalized patients with metastatic disease should be counseled before discharge, for example through outpatient transition [24], to reduce hospital readmission. Alternatively, down-staging efforts through an early stage at diagnosis, as secondary public health prevention, will indirectly reduce the rate of hospital readmission [2,9].

Similar to some but not all prior research, we found no association between readmission and comorbidities, LOS, or surgical approach. In a population-based study that assessed readmission rates in the VA population, the authors found no significant association between the aforementioned factors on the rate of readmission [25]. On the contrary, some other studies found a positive association with comorbidities, LOS, and open surgery. Notably, our population has longer index hospitalization compared to other populations [4,5,13,26]. It is possible that lack of association is due to the small

**Table 4** Univariate and multivariable analysis of risk factors for 30-day readmission, NGHA 2016–2021

	Univariate analysis		Multivariate analysis	
	OR	95% CI	OR	95% CI
Age				
≤ 40	1.0	1.0		
41–50	1.08	(0.24, 4.90)		
51–60	1.84	(0.49, 6.84)		
61–70	1.65	(0.44, 6.18)		
≥ 71	1.38	(0.36, 5.26)		
Gender				
Male	1.0	1.0		
Female	1.67	(0.91, 3.05)		
Marital status				
Single	1.0	1.0		
Married	2.92	(0.38, 22.56)		
Divorces/widowed	0.80	(0.05, 13.81)		
Unknown	1.82	(0.19, 17.69)		
Body mass index (BMI)				
Under weight	2.22	(0.63, 7.86)		
Healthy weight	1.0	1.0		
Overweight	0.55	(0.25, 1.19)		
Obese	0.71	(0.33, 1.51)		
CCI				
0	1.0	1.0		
1	0.69	(0.31, 1.57)		
> 1	0.97	(0.35, 2.67)		
Stage at diagnosis				
Localized	1.0	1.0	1.0	1.0
Regional	1.76	(0.59, 5.27)	1.59	(0.55, 4.58)
Distant metastasis	4.09	<b>(1.29, 12.98)</b>	<b>3.86</b>	<b>(1.26, 11.85)</b>
Missing	1.59	(0.16, 16.13)	2.19	(0.27, 17.45)
Pathological grading				
Well differentiated	1.0	1.0		
Moderately differentiated	0.89	(0.10, 7.65)		
Poorly differentiated	1.88	(0.18, 19.53)		
Unknown	1.09	(0.08, 14.66)		
Tumor morphology				
Adenocarcinoma (AC), NOS	1.0	1.0		
Mucinous AC	2.16	(0.42, 11.06)		
Others	1.17	(0.39, 3.59)		
Tumor site				
Right colon	1.0	1.0		
Left colon	1.41	(0.54, 3.72)		
Colon-nonspecified	1.29	(0.46, 3.65)		
Rectum	2.06	(0.71, 6.02)		
Chemotherapy				
Yes	1.0	1.0		
No	0.67	(0.28, 1.62)		
Radiotherapy				
Yes	1.0	1.0		

**Table 4** (continued)

	Univariate analysis		Multivariate analysis	
	OR	95% CI	OR	95% CI
No	0.65	(0.35, 1.22)		
Surgery approach				
Laparoscopic	1.0	1.0		
Open	1.24	(0.63, 2.45)		
Surgery type				
Elective	1.0	1.0		
Emergency	0.88	(0.33, 2.38)		
Other	0.4	(0.05, 3.10)		
LOS				
≤ 9 Days	1.0	1.0		
> 9 Days	1.29	(0.71, 2.37)		
Discharge location				
Central Post Anesthesia Care Unit	1.0	1.0	1.0	1.0
Intensive Care Unit	0.98	(0.39, 2.49)	1.0	(0.40, 2.48)
Other	3.75	<b>(1.19, 11.80)</b>	4.19	<b>(1.31, 13.42)</b>


Bold values indicate significant results at *p*-value = 0.05

observed number in the readmitted patients particularly those with > one comorbidity score.

The results of the present study should be interpreted within the scope of the following limitations. First, the reported results should be generalized to the MNG-HA population or a similar population. Second, SES is a factor that was affecting readmission in some previous studies which were not accounted for in the current study. Nonetheless, given that the MNG-HA population has equitable access to care and that all members are employed by the system, the SES effect is modest. Third, among patients with metastatic disease, we were not able to distinguish between primary tumor resection from metastatic resection. Fourth, given the positive volume-outcome relationship in CRC patients, adjusting for such factors could have improved the finding of the present study. Lastly, some of our admitted patients (*n* = 128) were missing discharge date and were excluded from analysis. The characteristics of these patients, nonetheless, were similar to our study population (Additional file 1: Appendix 2).

The knowledge of the rate and factors for hospital readmission in CRC patients has a significant impact on patients and the healthcare system. Given the identified factors, implementing strategies that may reduce readmission rates is needed. For instance, the adoption of minimally invasive surgery (e.g. laparoscopic procedure) could potentially contribute to lower hospitalization after major surgeries such as CRC. Additionally,





post-discharge strategies include shorter outpatient follow-up time, nursing or home health care visits, and making a nursing/ educator home phone call. Many other modalities may be studied and implemented.

**Conclusion**

CRC readmission is common, especially in patients with metastatic disease. Strategies to reduce readmission include planned transition to outpatient care, especially among patients with a high risk of readmission.

**Abbreviations**

CRC: Colorectal cancer; MNG-HA: Ministry of National Guard-Health Affairs; ICD: International classification of diseases; OS: Overall survival; SSI: Surgical site infections; CCI: Charlson comorbidity index; BMI: Body mass index.

**Supplementary Information**

The online version contains supplementary material available at <https://doi.org/10.1186/s12876-022-02516-2>.

**Additional file 1.** This file includes a table of the reasons for 30-day hospital readmission after surgery, in addition to another table representing a comparison between the study population and patients with missing discharge date.

**Acknowledgements**

The authors acknowledge the Research Data Management and Oncology Department at the Ministry of National Guard-Health Affairs (MNG-HA) for providing the data.

**Author contributions**

MSA designed the study, performed data analyses, and wrote the manuscript. AHA and LMA help with cleaning the data, reviewing the results, and writing the manuscript. MAA and KMA helped with data acquisition and interpretation as well as writing the manuscript. NAA analyzed the data, discussed the results, and wrote the manuscript. All authors approved the final version of the manuscript. All authors agree to be accountable for all aspects of the work.

**Funding**

There was no funding support for this work.

**Availability of data and materials**

The datasets generated and/or analysed during the current study are available from the corresponding author upon a reasonable request. The data are not publicly available due to privacy and ethical concerns by the Ethics Committee of the KAIMRC.

**Declarations**

**Ethics approval and consent to participate**

All methods were carried out in accordance with the Declaration of Helsinki. The study was reviewed and approved by King Abdullah International Medical Research Center (NRC21R/432/10), including the waiver of the informed consent.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

<sup>1</sup>Population Health Research Section, King Abdullah International Medical Research Center, PO Box 22490, Riyadh 11426, Saudi Arabia. <sup>2</sup>Population Health Research Section, King Abdul Aziz Medical City, King Abdullah International Medical Research Center, Jeddah 22384, Saudi Arabia. <sup>3</sup>Oncology Department, Ministry of National Guard - Health Affairs, Riyadh, Saudi Arabia.

<sup>4</sup>King Saud Bin Abdulaziz University for Health Sciences, PO Box 22490, Riyadh 11426, Saudi Arabia. <sup>5</sup>King Abdullah International Medical Research Center, PO Box 22490, Riyadh 11426, Saudi Arabia. <sup>6</sup>Health and Rehabilitation Sciences College, Princess Noura Bint Abdul Rahman University, Riyadh, Saudi Arabia. <sup>7</sup>King Abdullah International Medical Research Center, Mail Code 1515, P.O. Box 3660, Riyadh 11481, Saudi Arabia.

Received: 18 April 2022 Accepted: 23 September 2022  
Published online: 14 October 2022

## References

- Asefani M, et al. Population-based survival for cancer patients in Saudi Arabia for the years 2005–2009. *Sci Rep.* 2022;12:1–9.
- Alyabsi M, Alhumaid A, Allah-Bakhsh H, Alkelya M, Aziz MA. Colorectal cancer in Saudi Arabia as the proof-of-principle model for implementing strategies of predictive, preventive, and personalized medicine in health-care. *EPMA Journal*, 1–13 (2019).
- Provenzale D, et al. NCCN guidelines insights: colorectal cancer screening, version 1.2018. *J Natl Compr Cancer Netw.* 2018;16:939–49.
- Greenblatt DY, et al. Readmission after colectomy for cancer predicts one-year mortality. *Ann Surg.* 2010;251:659–69. <https://doi.org/10.1097/SLA.0b013e3181d3d27c>.
- Bartlett EK, Hoffman RL, Mahmoud NN, Karakousis GC, Kelz RR. Postdischarge occurrences after colorectal surgery happen early and are associated with dramatically increased rates of readmission. *Dis Colon Rectum.* 2014;57:1309–16. <https://doi.org/10.1097/dcr.000000000000212>.
- Wick EC, et al. Readmission rates and cost following colorectal surgery. *Dis Colon Rectum.* 2011;54:1475–9. <https://doi.org/10.1097/DCR.0b013e31822ff8f0>.
- Solomon R, et al. Thirty-day readmissions in patients with metastatic cancer: room for improvement? *J Oncol Pract.* 2019;15:e410–9.
- Damle RN, Alavi K. Risk factors for 30-d readmission after colorectal surgery: a systematic review. *J Surg Res.* 2016;200:200–7. <https://doi.org/10.1016/j.jss.2015.06.052>.
- Alyabsi M, Sabatin F, Jazieh AR. The outcome of unscreened population in colorectal cancer: the impact of sex and other determinants on cancer stage. *Cancer Manag Res.* 2020;12:12319.
- Ministry of Health. Statistical Yearbook 2020, <Available from: <https://www.moh.gov.sa/en/Ministry/Statistics/book/Pages/default.aspx>> (2020).
- Alyabsi M, Sabatin F, Ramadan M, Jazieh AR. Colorectal cancer survival among Ministry of National Guard-Health Affairs (MNG-HA) population 2009–2017: retrospective study. *BMC Cancer.* 2021;21:1–11.
- Pucciarelli S, et al. In-hospital mortality, 30-day readmission, and length of hospital stay after surgery for primary colorectal cancer: a national population-based study. *Eur J Surg Oncol (EJSO).* 2017;43:1312–23.
- Schneider EB, et al. Patient readmission and mortality after colorectal surgery for colon cancer: impact of length of stay relative to other clinical factors. *J Am Coll Surg.* 2012;214:390–8. <https://doi.org/10.1016/j.jamcollsurg.2011.12.025> (Discussion 398–399).
- Saunders N, et al. Examination of unplanned 30-day readmissions to a comprehensive cancer hospital. *J Oncol Pract.* 2015;11(2):e177–81.
- Kiran RP, et al. Outcomes and prediction of hospital readmission after intestinal surgery. *J Am Coll Surg.* 2004;198:877–83.
- Kariv Y, et al. Multivariable analysis of factors associated with hospital readmission after intestinal surgery. *Am J Surg.* 2006;191:364–71. <https://doi.org/10.1016/j.amjsurg.2005.10.038>.
- Al-Mazrou AM, Suradkar K, Mauro CM, Kiran RP. Characterization of readmission by day of rehospitalization after colorectal surgery. *Dis Colon Rectum.* 2017;60:202–12.
- Brooks GA, et al. Identification of potentially avoidable hospitalizations in patients with GI cancer. *J Clin Oncol.* 2014;32:496.
- Shapiro JS, et al. Risk factors for readmission in patients with Cancer Comanaged by hospitalists. *Am J Med Qual.* 2017;32:526–31.
- Epstein AS, et al. 30-day-or-sooner readmissions of gastrointestinal medical oncology patients following cancer center inpatient service discharge: characteristics and preventability. *Hosp Pract.* 2014;42:34–44.
- Manzano J-GM, et al. Unplanned 30-day readmissions in a general internal medicine hospitalist service at a comprehensive cancer center. *J Oncol Pract.* 2015;11:410–5.
- González JR, et al. Sex differences in hospital readmission among colorectal cancer patients. *J Epidemiol Community Health.* 2005;59:506–11.
- Chung JS, Kwak HD, Ju JK. Thirty-day readmission after elective colorectal surgery for colon cancer: a single-center cohort study. *Ann Coloproctol.* 2020;36:186.
- Montero AJ, et al. Reducing unplanned medical oncology readmissions by improving outpatient care transitions: a process improvement project at the Cleveland Clinic. *J Oncol Pract.* 2016;12:e594–602.
- Orcutt ST, et al. Ninety-day readmission after colorectal cancer surgery in a Veterans Affairs cohort. *J Surg Res.* 2016;201:370–7.
- Damle RN, et al. Clinical and financial impact of hospital readmissions after colorectal resection: predictors, outcomes, and costs. *Dis Colon Rectum.* 2014;57:1421–9. <https://doi.org/10.1097/dcr.0000000000000251>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

